Genetic Chemistry Inc., a Bay Area subsidiary of Evolva SA, secured a contract worth up to $22.8 million from the U.S. Army Research Office to discover and develop novel compounds that act against the Gram-negative bacterium Burkholderia pseudomallei. (BioWorld International)

Shares of Iomai Corp. surged more than 117 percent after the firm agreed to be acquired by Austrian vaccines maker Intercell AG in a deal valued at about $189 million. (BioWorld Today)

In a move that will add two Phase II development programs to its pipeline, Intercell AG entered an agreement to acquire Gaithersburg, Md.-based Iomai Corp. in a cash-and-shares deal valued, on a fully diluted basis, at approximately $189 million. (BioWorld International)

MTM Laboratories AG added another E9.6 million (US$15.3 million) to its Series C financing round, taking the total to E31.6 million and giving the company additional funds for further clinical development of its biomarker-based diagnostic assays for cervical cancer and for building out its sales and marketing infrastructure. (BioWorld International)